Toward Clinical Translation in Huntington’s Disease: An Integrated Small-Molecule & Cell Therapy Strategy
- Overview of iPS Bio’s translational strategy for Huntington’s disease, integrating disease-modifying small-molecule approaches with allogeneic iPSCderived neural precursor cell therapy
- Exploring the preclinical development of iPS Bio’s therapeutic programs, including patient-derived iPSC disease models, in vivo efficacy studies, mechanism-of-action considerations, and translational biomarkers
- Revealing key challenges and opportunities in advancing Huntington’s disease therapeutics toward clinical translation, including CMC, safety, regulatory strategy, patient selection, and global collaboration